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Abstract 
Introduction: Herpes zoster, shingles, is a secondary pathology due 
to a reactivation of the varicella-zoster virus (VZV) and common in the 
general population. It is responsible for a painful skin rash localized in the area 
of the body innervated by a nerve root. The rash can be widespread affecting 
several dermatomes especially in the immunocompromised subject. 
Observation: We report an observation of disseminated shingles in an 
immunocompetent adult hospitalized in the Internal Medicine Department of 
Zinder National Hospital. AT 55 years old, was admitted for management of 
a very painful skin rash. Pruriginous vesicles extended diffusely out of the 
metameric topography to all the enveloping membranes of the body including 
vulvo-vaginal and oral enanthem. Biologically, blood count (CBC), blood 
glucose, and renal function were normal. Human immunodeficiency virus 
(HIV) status was negative. The clinical course was uneventful characterized 
by apyrexia at 48 hours and drying of the lesions. Medical care was based on 
symptomatic treatment. Conclusion: Shingles is a common viral disease, but 
potentially serious in some situations. The disseminated form is exceptional in 
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the immunocompetent subject. Its detection and early treatment ensure a 
reduction in the severity of the complications. 
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Introduction 
Herpes zoster, shingles, is the clinical expression of reactivation of the 
varicella zoster virus (VZV). It is a DNA virus belonging to the herpesviridae 
family and of strictly inter-human transmission (1). Its incidence varies with 
age, from 3/1000 before the age of 30 to 8/1000 after age 60 (2–4). VZV 
infections are generally benign, but severe and disseminated forms are 
possible in immunocompromised individuals as well as in immunocompetent 
adults (1). The risk of disseminated shingles in subjects with malignant disease 
is 100 times higher than in healthy subjects (5). The clinical picture is that of 
a diffuse rash or even true chickenpox,  much more often resurgences of 
previous infections than primary infections (6). Few authors have described 
disseminated shingles in the immunocompetent (2).  We report a disseminated 
case of herpes zoster in an immunocompetent adult hospitalized at the Internal 
Medicine Department of Zinder National Hospital. 
 
Patient and method 
AT 55 years old, gravida 9, para 9, widowed 5 years previously, no 
significant pathological antecedents, especially childhood eruptive diseases 
and congenital or acquired immunodepression. The patient was admitted to 
internal medicine for management of a very painful skin rash in a context of 
intense physical asthenia, weight was 60kg, height 1.62m or a BMI of 
22kg/m2. The anamnesis revealed that symptoms began seven (7) days earlier 
with a tingling followed by the appearance of erythema accompanied by pain 
in the thoracolumbar hemi-belt region. Four (4) days later a vesicular 
exanthem appeared first in clusters then in confluent polycyclic blisters. These 
pruriginous vesicles extended diffusely out of the metameric topography (Fig 
1 and 2) to all the enveloping membranes of the body including vulvo-vaginal 
and oral enantham. The diagnosis of generalized shingles was made on the 
basis of the singular nature of the lesions. Clinical examination elsewhere, 
specifically lymphatic and neurological, was without particularity.  
Biologically, blood count (CBC), blood glucose, and renal function 
were normal. Human immunodeficiency virus (HIV) serology was negative. 
Medical care was based on symptomatic treatment with analgesics 
(paracetamol 1 gram 3 times a day and tramadol 100mg three times a day), 
antihistamines (hydroxizine 25 mg per day), antiseptics (aqueous Eosin 2% 
two daily applications) and antiviral treatment based on oral acyclovir (10 mg 
per kg every 8 hours). The clinical course was favourable; characterized by 
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apyrexia after 48 hours and the drying of lesions with crust formation within 
seven days. 
 
Images 
Figure 1: Band of disseminated rash on the abdomen and back. 
 
 
Figure 2: Vesicular rash on the forehead and scalp 
 
Discussion 
The VZV seroprevalence in the general population is extremely high, 
around 98% in adults  (1). Incidence increases from 3/1000 before 30 years to 
more than 8/1000 after 30 years (2). The occurrence of chicken pox before one 
year of age is a predisposition to the onset of shingles before the age of 60 (7). 
Risk factors that may trigger or aggravate shingles are: age, 
immunodeficiency, diabetes, stress (8). Our patient was 55 years old. In the 
Gargouri series, out of 115 patients followed for shingles from 2005 to 2015 
at the Sfax infectious diseases department in Tunisia, the mean age was 56 ± 
17 years (9). Beyond her age, the only other risk factor cited in the literature 
found in our patient was stress. In fact, our patient had lost her husband and 
had a hard time providing for her family. Stress, especially in the 6 months 
preceding shingles, may have a role in promoting the reactivation of VZV by 
altering the cellular immunity of subjects (10). Our patient’s 
immunosuppression assessment was not exhaustive due to the technical 
limitations of our laboratory. It included a blood count, liver and kidney 
biology report, HIV serology, neoplastic and diabetic status, and an 
assessment of nutritional status. Complementary measures, plasma protein 
electrophoresis, and specific immunoglobulin assays were not performed.  
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Clinically after a silent 14-day incubation, the invasion phase is short (24 
hours), characterized by a febrile prodromal syndrome with discomfort (1). 
The usual clinical presentation begins with an abnormal skin sensation, then 
pain of varying intensity (respecting a dermatome) preceding a rash of 1 to 5 
days. The erythematous-maculopapular rash is followed by the formation of 
vesicles evolving towards ulceration then the formation of crusts.  The 
dermatome area may be exceeded in 20% of cases. Observations of 
simultaneous involvement of several dermatomes have been reported but 
never in immunocompetent individuals (8). This reflects the singularity of our 
observation. Indeed, in our patient we observed a diffuse alveolar vesicular 
rash outside the metameric topography (Fig 1 and 2) to all the enveloping 
membranes of the body including vulvo-vaginal and oral enantham. A true 
"varicella -zoster" (Fig. 1, 2). 
Therapeutically, the recommended regimens for the 
immunocompetent subject are: oral valacyclovir, 3 doses of 1 g / day for 7 
days; oral famciclovir, 3 doses of 500 to 750 mg / day for 7 days (11,12); with 
3 doses of 500 mg/day advised. There is no benefit in extending the duration 
of treatment beyond 7 days. The addition of a corticosteroid does not increase 
the effectiveness of the antiviral drug (13). Studies have shown that these 
antivirals, compared to placebo, can shorten the duration of the acute episode, 
limit the appearance of new lesions, accelerate recovery and reduce acute pain. 
(14). In addition, a meta-analysis showed that acyclovir was significantly 
superior to placebo in reducing the duration of zoster pain (15). Tricyclic 
antidepressants are of major interest in the treatment of post-herpetic 
neuralgia. Of these, amitriptyline has been the most studied; taken orally, at a 
dosage ranging from 10 to 150 mg / day, it has a proven efficacy after 3 to 6 
weeks (16). Our patient was treated with acyclovir and the clinical course was 
favourable characterized by apyrexia at 48 hours and dryness of the lesions 
with formation of crusts within 7 days. 
The introduction of the VZV vaccine and especially the 
recommendation of a second injection to prolong the induced immunity should 
help reduce the incidence of shingles in the population (17,18). Immunization 
efficiency is estimated at 85% according to the special issue of the Journal of 
Infectious Disease (19) which completes the 2007 article of the New England 
Journal of Medicine (17) presenting the results of the first ten years of this 
vaccine in the USA. The VZV vaccine is not yet in the Expanded Program on 
Immunization in Niger and would be a good alternative to prevent shingles in 
the country. 
 
Conclusion 
Shingles is a common viral disease, but potentially serious in some 
situations. The disseminated form is exceptional in the immunocompetent 
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subject. Its detection and early treatment ensures a reduction in the severity of 
the complications. 
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